EXEL – Exelixis, Inc.

EXEL — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

10.5

Margin Of Safety %

Put/Call OI Ratio

0.8

EPS Next Q Diff

-0.13

EPS Last/This Y

0.52

EPS This/Next Y

0.53

Price

43.99

Target Price

46.83

Analyst Recom

2.14

Performance Q

3.75

Upside

121.2%

Beta

0.4

Ticker: EXEL

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	EXEL	42.35	0.86	1.47	30903
2026-03-10	EXEL	41.31	0.84	1.73	30842
2026-03-11	EXEL	41.75	0.84	0.08	30850
2026-03-12	EXEL	41.16	0.86	0.42	30584
2026-03-13	EXEL	41.17	0.86	0.24	30584
2026-03-17	EXEL	41.85	0.85	0.21	30782
2026-03-18	EXEL	41.26	0.86	0.08	30702
2026-03-19	EXEL	41.25	0.85	1.80	30843
2026-03-20	EXEL	41.21	0.85	0.16	30836
2026-03-23	EXEL	41.41	0.82	0.30	24380
2026-03-24	EXEL	41.56	0.81	0.72	24574
2026-03-25	EXEL	42.79	0.81	0.23	24656
2026-03-26	EXEL	42.37	0.80	0.22	24863
2026-03-27	EXEL	41.53	0.80	0.07	24941
2026-03-30	EXEL	41.93	0.78	1.06	25221
2026-03-31	EXEL	42.91	0.79	0.33	25358
2026-04-01	EXEL	44.04	0.77	0.18	25607
2026-04-02	EXEL	43.88	0.77	0.17	25870
2026-04-06	EXEL	43.99	0.80	4.50	25174
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	EXEL	42.36	22.2	-5.9	3.39
2026-03-10	EXEL	41.31	22.2	-48.0	3.39
2026-03-11	EXEL	41.74	22.2	-13.9	3.39
2026-03-12	EXEL	41.17	22.2	-37.6	3.40
2026-03-13	EXEL	41.24	22.2	-22.5	3.40
2026-03-17	EXEL	41.85	22.2	-6.3	3.40
2026-03-18	EXEL	41.26	22.2	-37.1	3.40
2026-03-19	EXEL	41.26	22.2	-112.5	3.40
2026-03-20	EXEL	41.27	22.2	-112.4	3.40
2026-03-23	EXEL	41.42	22.2	-109.1	3.40
2026-03-24	EXEL	41.58	22.2	-105.9	3.40
2026-03-25	EXEL	42.79	22.2	-80.9	3.40
2026-03-26	EXEL	42.37	22.2	-89.7	3.40
2026-03-27	EXEL	41.53	22.2	-106.7	3.40
2026-03-30	EXEL	41.94	22.2	-98.3	3.40
2026-03-31	EXEL	42.89	22.2	-78.8	3.40
2026-04-01	EXEL	44.04	22.2	-55.1	3.40
2026-04-02	EXEL	43.88	22.2	-58.4	3.40
2026-04-06	EXEL	43.99	22.2	-56.2	3.40
2026-04-07	EXEL	43.99	22.2	-58.2	3.40
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	EXEL	-7.36	3.01	11.47
2026-03-10	EXEL	-7.36	3.01	11.47
2026-03-11	EXEL	-7.36	3.01	10.48
2026-03-12	EXEL	-7.36	3.01	10.48
2026-03-13	EXEL	-7.36	3.01	10.48
2026-03-17	EXEL	-7.36	3.04	10.48
2026-03-18	EXEL	-7.36	3.04	10.48
2026-03-19	EXEL	-7.36	3.04	10.48
2026-03-20	EXEL	-7.36	3.04	10.48
2026-03-23	EXEL	-7.36	3.07	10.48
2026-03-24	EXEL	-7.36	3.07	10.48
2026-03-25	EXEL	-7.36	3.07	10.50
2026-03-26	EXEL	-7.36	3.07	10.50
2026-03-27	EXEL	-7.36	3.07	10.50
2026-03-30	EXEL	-7.36	3.07	10.50
2026-03-31	EXEL	-7.36	3.07	10.50
2026-04-01	EXEL	-7.36	3.07	10.50
2026-04-02	EXEL	-7.36	3.07	10.50
2026-04-06	EXEL	-7.36	3.07	10.50
2026-04-07	EXEL	-7.36	3.07	10.50
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.94

Avg. EPS Est. Current Quarter

0.76

Avg. EPS Est. Next Quarter

0.81

Insider Transactions

-7.36

Institutional Transactions

3.07

Beta

0.4

Average Sales Estimate Current Quarter

607

Average Sales Estimate Next Quarter

630

Fair Value

44.5

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

11.3

Max Drawdown 5-Year %

-41.5

Target Price

46.83

P/E

15.8

Forward P/E

11.21

PEG

0.71

P/S

4.92

P/B

5.34

P/Free Cash Flow

13.04

EPS

2.78

Average EPS Est. Cur. Y

3.4

EPS Next Y. (Est.)

3.93

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

33.73

Relative Volume

0.86

Return on Equity vs Sector %

8.7

Return on Equity vs Industry %

25.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

-58.2

◆ EXEL Healthcare

$43.99

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

10/20

Pullback

10/25

Volume

4/15

Valuation

10/20

TP/AR

1/10

Options

0/10

RSI

60.5

Range 1M

88.8%

Sup Dist

0.8%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

16/30

Estimates

6/20

Inst/Vol

6/15

Options

0/10

EPS Yr

7.8%

EPS NY

18.2%

52W%

67.5%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +108% upside

Quality

28/30

Valuation

20/30

Growth

13/25

Stability

8/10

LT Trend

2/5

Upside

+108%

Quality

MoS

Exelixis, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1077

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

EXEL

Latest News

—

Caricamento notizie per EXEL…

stock quote shares EXEL – Exelixis, Inc. Stock Price stock today

news today EXEL – Exelixis, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EXEL – Exelixis, Inc. yahoo finance google finance

stock history EXEL – Exelixis, Inc. invest stock market

stock prices EXEL premarket after hours

ticker EXEL fair value insiders trading

EXEL – Exelixis, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: EXEL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y